Beddow Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $0 | Sell |
505,289
-17,500
| -3% | – | ﹤0.01% | 55 |
|
|
2025
Q3 | $0 | Hold |
522,789
| – | – | ﹤0.01% | 57 |
|
|
2025
Q2 | $0 | Sell |
522,789
-29,750
| -5% | – | ﹤0.01% | 57 |
|
|
2025
Q1 | $0 | Sell |
552,539
-1,250
| -0.2% | – | ﹤0.01% | 59 |
|
|
2024
Q4 | $0 | Hold |
553,789
| – | – | ﹤0.01% | 59 |
|
|
2024
Q3 | $0 | Hold |
553,789
| – | – | ﹤0.01% | 60 |
|
|
2024
Q2 | $0 | Sell |
553,789
-7,000
| -1% | – | ﹤0.01% | 59 |
|
|
2024
Q1 | $0 | Hold |
560,789
| – | – | ﹤0.01% | 60 |
|
|
2023
Q4 | $0 | Sell |
560,789
-1,750
| -0.3% | – | ﹤0.01% | 58 |
|
|
2023
Q3 | $0 | Sell |
562,539
-8,590
| -2% | – | ﹤0.01% | 55 |
|
|
2023
Q2 | $0 | Hold |
571,129
| – | – | ﹤0.01% | 54 |
|
|
2023
Q1 | $0 | Hold |
571,129
| – | – | ﹤0.01% | 54 |
|
|
2022
Q4 | $0 | Sell |
571,129
-1,750
| -0.3% | – | ﹤0.01% | 52 |
|
|
2022
Q3 | $0 | Hold |
572,879
| – | – | ﹤0.01% | 51 |
|
|
2022
Q2 | $0 | Hold |
572,879
| – | – | ﹤0.01% | 54 |
|
|
2022
Q1 | $0 | Buy |
572,879
+357,579
| +166% | – | ﹤0.01% | 57 |
|
|
2021
Q4 | $0 | Sell |
215,300
-354,989
| -62% | – | ﹤0.01% | 52 |
|
|
2021
Q3 | $0 | Hold |
570,289
| – | – | ﹤0.01% | 57 |
|
|
2021
Q2 | $0 | Sell |
570,289
-1,500
| -0.3% | – | ﹤0.01% | 60 |
|
|
2021
Q1 | $0 | Hold |
571,789
| – | – | ﹤0.01% | 59 |
|
|
2020
Q4 | $395K | Buy |
571,789
+43,006
| +8% | +$91.6K | 0.28% | 40 |
|
|
2020
Q3 | $1.19M | Buy |
528,783
+50,925
| +11% | +$145K | 1.02% | 26 |
|
|
2020
Q2 | $1.68M | Sell |
477,858
-16,025
| -3% | -$57.8K | 1.47% | 26 |
|
|
2020
Q1 | $1.91M | Buy |
+493,883
| New | +$1.63M | 1.75% | 25 |
|
Beddow Capital Management's BMY.RT Position: Q4 2025 in Review
Beddow Capital Management reduced its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) stake by 3.3% in Q4 2025, cutting 17,500 shares and leaving 505,289 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #55.
Beddow Capital Management first reported a position in BMY.RT in Q1 2020 and has held it in 24 quarters since. The position peaked at $1.91M in Q1 2020. 1 fund tracked by Wall St. Rank holds BMY.RT as of Q4 2025.
- Beddow Capital Management held 505,289 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $0 as of Q4 2025.
- Beddow Capital Management sold 17,500 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2025.
- Bristol-Myers Squibb Company Contingent Value Rights made up ﹤0.01% of Beddow Capital Management's portfolio in Q4 2025, its #55 holding.
- Beddow Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and has held it in 24 quarters since.
- Beddow Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.91M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2025.
Based on Beddow Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.